Liminatus Pharma (LIMN) Competitors $1.61 -0.18 (-10.09%) As of 02:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock LIMN vs. GNFT, TLSA, MDWD, TRDA, SLS, HRTX, EPRX, DERM, IPHA, and CCCCShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include GENFIT (GNFT), Tiziana Life Sciences (TLSA), MediWound (MDWD), Entrada Therapeutics (TRDA), SELLAS Life Sciences Group (SLS), Heron Therapeutics (HRTX), Eupraxia Pharmaceuticals (EPRX), Journey Medical (DERM), Innate Pharma (IPHA), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors GENFIT Tiziana Life Sciences MediWound Entrada Therapeutics SELLAS Life Sciences Group Heron Therapeutics Eupraxia Pharmaceuticals Journey Medical Innate Pharma C4 Therapeutics GENFIT (NASDAQ:GNFT) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Is GNFT or LIMN more profitable? Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A Liminatus Pharma N/A N/A N/A Do insiders and institutionals believe in GNFT or LIMN? 2.2% of GENFIT shares are held by institutional investors. 4.2% of GENFIT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend GNFT or LIMN? GENFIT currently has a consensus price target of $9.00, indicating a potential upside of 113.02%. Given GENFIT's stronger consensus rating and higher possible upside, equities analysts plainly believe GENFIT is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, GNFT or LIMN? GENFIT has higher revenue and earnings than Liminatus Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.75$1.63MN/AN/ALiminatus PharmaN/AN/AN/AN/AN/A Does the media favor GNFT or LIMN? In the previous week, GENFIT and GENFIT both had 1 articles in the media. Liminatus Pharma's average media sentiment score of 1.91 beat GENFIT's score of 1.89 indicating that Liminatus Pharma is being referred to more favorably in the news media. Company Overall Sentiment GENFIT Very Positive Liminatus Pharma Very Positive SummaryGENFIT beats Liminatus Pharma on 6 of the 7 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$41.88M$236.20M$2.55B$10.26BDividend YieldN/AN/A2.49%4.63%P/E RatioN/AN/A26.5026.57Price / SalesN/A215.40110.62122.51Price / CashN/AN/A48.9160.49Price / BookN/A2.6135.806.34Net IncomeN/A-$111.70M$15.01M$270.99M7 Day Performance-20.69%-5.87%1.15%2.67%1 Month Performance-59.75%-39.83%4.35%7.23%1 Year PerformanceN/A57.10%50.64%27.97% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$1.61-10.1%N/AN/A$41.86MN/A0.00N/APositive NewsGNFTGENFIT1.9155 of 5 stars$4.14-3.2%$9.00+117.7%+1.3%$206.76M$67.00M0.00120Positive NewsUpcoming EarningsTLSATiziana Life Sciences0.5867 of 5 stars$1.74-5.9%N/A+96.5%$203.32MN/A0.008Short Interest ↑MDWDMediWound1.7071 of 5 stars$18.45+13.3%$32.25+74.8%-5.4%$199.44M$20.22M-6.9980News CoverageGap UpHigh Trading VolumeTRDAEntrada Therapeutics2.539 of 5 stars$5.22+1.6%$25.67+391.7%-64.8%$198.57M$210.78M-2.93110SLSSELLAS Life Sciences Group1.3413 of 5 stars$1.88+1.1%$7.00+272.3%+28.5%$197.96MN/A-5.8810HRTXHeron Therapeutics4.1168 of 5 stars$1.27-2.3%$4.50+254.3%-32.2%$194.68M$144.29M-63.50300Positive NewsEPRXEupraxia Pharmaceuticals2.2942 of 5 stars$5.32flat$11.00+106.8%+108.2%$191.31MN/A-6.2629DERMJourney Medical2.3753 of 5 stars$7.23-3.0%$12.17+68.3%+32.0%$190.22M$56.40M-19.0390IPHAInnate Pharma2.6237 of 5 stars$2.06+0.5%$11.00+434.0%-4.1%$189.90M$12.62M0.00220News CoveragePositive NewsCCCCC4 Therapeutics3.1167 of 5 stars$2.64-1.5%$8.00+203.0%-46.4%$187.89M$34.24M-1.67150News CoverageAnalyst Upgrade Related Companies and Tools Related Companies GENFIT Competitors Tiziana Life Sciences Competitors MediWound Competitors Entrada Therapeutics Competitors SELLAS Life Sciences Group Competitors Heron Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Journey Medical Competitors Innate Pharma Competitors C4 Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIMN Stock Alerts